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Background: Glioma imaging, used for diagnostics, treatment planning and follow-up, is 1 
currently based on standard magnetic resonance imaging (MRI) modalities (T1 contrast-2 
enhancement for gadolinium-enhancing gliomas and T2/ Fluid attenuated inversion 3 
recovery (FLAIR) hyperintensity for non-enhancing gliomas). The diagnostic accuracy of 4 
these techniques for the delineation of gliomas is suboptimal. 5 
Objective: To assess the diagnostic accuracy of advanced neuroimaging compared with 6 
standard MRI modalities for the detection of diffuse glioma infiltration within the brain. 7 
Methods: A monocenter, prospective, diagnostic observational study in adult patients 8 
with a newly diagnosed, diffuse infiltrative glioma undergoing resective glioma surgery. 9 
Forty patients will be recruited in three years. Advanced neuroimaging will be added to 10 
the standard preoperative MRI. Serial neuronavigated biopsies in and around the glioma 11 
boundaries, obtained immediately preceding resective surgery, will provide 12 
histopathologic and molecular characteristics of the regions of interest, enabling 13 
comparison with quantitative measurements in the imaging modalities at the same 14 
biopsy sites.   15 
Expected outcome: We hypothesize that a combination of positron emission 16 
tomography, MR spectroscopy and standard MRI will have a superior accuracy for 17 
glioma delineation compared to standard MRI alone. In addition, we anticipate that 18 
advanced imaging will correlate with the histopathologic and molecular characteristics 19 
of glioma.  20 
Discussion: In this clinical study, we determine the diagnostic accuracy of advanced 21 
imaging in addition to standard MRI to delineate glioma. The results of our study can be 22 
valuable for the development of an improved standard imaging protocol for glioma 23 
treatment.  24 
 25 
General information 26 
The study is titled: ‘Frontiers in advanced imaging of unexplored glioma regions 27 
(FRONTIER study)’ (www.trialregister.nl, unique identifier NTR5354). Overall study 28 
dates are September 2014 to September 2017. Funding agencies: Cancer Center 29 
Amsterdam and the Dutch Cancer Society.  30 
Investigation site: VU University Medical Center (VUmc), P.O. Box 7057, 1007 MB 31 
Amsterdam, The Netherlands.  32 
Principle investigator: P.C. de Witt Hamer, MD, PhD, Department of Neurosurgery. 33 
 2 
Investigators: W.P. Vandertop, MD, PhD, and N. Verburg, MD, Department of 34 
Neurosurgery; J.C. Reijneveld, MD, PhD, Department of Neurology; P. Wesseling, MD, 35 
PhD, Department of Pathology; P.J.W. Pouwels, PhD, Department of Physics & Medical 36 
Technology; F. Barkhof, MD, PhD, R. Boellaard, MSc, PhD and O.S. Hoekstra, MD, PhD, 37 
Department of Nuclear Medicine & PET Research.   38 
 39 
Rationale and background information 40 
Gliomas represent 80-90% of parenchymal brain tumors in adults with an incidence of 41 
5.9 per 100.000 person-years: approximately 1000 patients per year in The 42 
Netherlands. 1 Most gliomas show extensive infiltration in the brain parenchyma. These 43 
so-called diffuse gliomas universally recur, without exception resulting in death despite 44 
standard treatment, which consists of as extensive as possible resection, followed by 45 
radiation and chemotherapy.  46 
Both resective surgery and adjuvant radiation therapy are based on T1 contrast-47 
enhancement for gadolinium-enhancing gliomas and on T2/ Fluid attenuated inversion 48 
recovery (FLAIR) hyperintensity volume outlines for non-enhancing gliomas. This 49 
strategy is founded on early and preliminary observations, and has remained unchanged 50 
since. 2, 3 Diffuse gliomas recur locally in the vast majority of patients, even after 51 
seemingly radical surgical removal and radiation therapy with 2 cm margins. This, and 52 
the fact that glioma infiltration has been demonstrated to extend up to two centimeters 53 
beyond standard MRI outlines, underscores that up till now delineation of these 54 
neoplasms has been less than optimal. 4-7  55 
Several publications provide arguments for underestimation of the spread of diffuse 56 
gliomas using standard MRI and potential benefit from advanced MRI and positron 57 
emission tomography (PET) imaging. Advanced imaging, such as diffusion-weighted 58 
imaging (DWI), perfusion-weighted imaging (PWI), magnetic resonance spectroscopy 59 
(MRS) and PET, has been shown to be able to identify tumor in areas of normal standard 60 
MRI signal. 8-10  61 
Our study addresses a clinically relevant research question, which so far has not been 62 
adequately answered: What is the best neuroimaging approach to discriminate areas 63 
with glioma infiltration from brain tissue without glioma cells?  64 
 65 
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Study Goals and Objectives 66 
The goal of this study is thus to determine the best neuroimaging approach for glioma 67 
delineation.  68 
The specific objectives are: 69 
- To assess the increase in diagnostic accuracy of adding advanced neuroimaging 70 
modalities to standard MRI for the detection of diffuse glioma infiltration within 71 
the brain 72 
- To correlate the information obtained by standard and advanced imaging to 73 
histologic and molecular characteristics of the tissue. 74 
We hypothesize that advanced neuroimaging, in combination with standard MRI, will 75 
have a superior diagnostic accuracy in comparison with standard MRI alone. Besides, we 76 
hypothesize that histological and molecular characteristics of (different areas of) glioma 77 
will correlate better with advanced imaging than with standard imaging.  78 
 79 
Study Design 80 
The study design is a monocenter, prospective, diagnostic observational study. 81 
 82 
Methodology 83 
Subjects 84 
Inclusion criteria 85 
Patients of 18 years and older with a MRI interpretation of a diffuse glioma by an 86 
experienced neuroradiologist, and who have an indication for resective surgery; the 87 
indication confirmed by the multidisciplinary neuro-oncology tumor board. 88 
 89 
Exclusion criteria 90 
Patients who are pregnant or have undergone previous brain surgery, cranial irradiation 91 
or chemotherapy. Patients with other brain pathology on MRI, such as stroke or multiple 92 
sclerosis. Patients with a tumor located infratentorially or in the spinal cord. 93 
 94 
Withdrawal criteria 95 
Patients who do not successfully undergo one PET scan. A summary of all criteria is 96 
given in table 1.  97 
 98 
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Study description 99 
The study is separated into two phases (Figure 1). In both phases, standard and 100 
advanced imaging will be performed pre-operatively (Table 2). Immediately preceding 101 
resective surgery, serial image-guided neuronavigated biopsies in and around the 102 
glioma boundaries will be obtained using a stereotactic drilling technique.11 Two 103 
samples are collected from each biopsy location, one for assessment of histopathologic 104 
characteristics and one for molecular analysis.  105 
Phase I is designed to decide on the optimal PET tracer, to simplify PET scanning 106 
methodology and to develop a robust MRI protocol for glioma volume estimation. Eight 107 
patients will receive a dynamic PET protocol with invasive blood sampling, and image-108 
derived carotid input function for metabolite analysis of  109 
[18F-]Fluoroethyl-tyrosine (FET) and [11C-]Choline (CHO) tracers, as well as advanced 110 
MR imaging. The data obtained will be used to establish a simplified PET protocol and to 111 
determine which of both PET tracers will be further pursued in the next study phase.  112 
To obtain a total sample size of 20 patients with a high-grade glioma (WHO grade III or 113 
IV) and 20 with a low-grade glioma (WHO grade II), 20 additional patients will receive 114 
single advanced MRI and selected simplified PET imaging in the second phase to 115 
complete the data acquisition according to the sample size calculation for the main 116 
research question.  117 
 118 
Outcome measures 119 
MRI 120 
MRI will be performed using the Philips Achieva whole-body 3.0T MR-scanner, equipped 121 
with the standard head coil. Table 2 shows the different techniques. 122 
 123 
PET 124 
PET will be performed using the Philips Gemini time-of-flight (TOF) PET-CT scanner or 125 
the Philips Ingenuity TOF PET/MRI-scanner. After intravenous administration of 370 126 
megabecquerel (MBq) of [15O]H2O a 10 min dynamic scan is acquired. This is followed 127 
by a 40 min dynamic scan after injection of 200 MBq CHO. With a minimum of 4 hours 128 
after injection of CHO the FET scan will be performed the same day using 200 MBq FET 129 
and a scan time of 90 minutes. During the scans manual blood samples are withdrawn in 130 
order to calibrate the online collected arterial input functions and to derive a fully 131 
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metabolite-corrected plasma input function. 132 
 133 
Of each biopsy site qualitative (high, normal or low signal) and quantitative parameters 134 
will be acquired by an experienced neuroradiologist and a nuclear medicine physician 135 
(Table 2).  136 
 137 
Pathology  138 
Of each biopsy location one sample will be processed for histopathologic analysis and 139 
the other sample for molecular analysis. Histopathologic analysis will be performed 140 
using hematoxylin-and-eosin (H&E) staining and immunohistochemical markers to 141 
assess cellularity, glioma infiltration, proliferation, microvascular changes, and necrosis. 142 
Molecular analysis will include assessment of DNA mutations, deletions, amplifications 143 
and RNA expression profiling. Two experienced neuropathologists will evaluate 144 
independently, and blinded for the imaging results, all biopsies and designate those as: 145 
normal brain tissue; diffuse glioma with few, moderate or many tumor cells in a 146 
background of pre-existent brain tissue; highly cellular glioma without (apparent) 147 
preexistent brain tissue remaining; uninformative.  148 
 149 
Discussion 150 
Few studies investigate the diagnostic accuracy of glioma delineation, and most of these 151 
studies assess only one or two imaging modalities. This can at least partly be explained 152 
by the logistic challenge of multimodality preoperative imaging and of obtaining 153 
multiple image-guided biopsies. Nevertheless, studies that provide a direct comparison 154 
of multiple imaging modalities with histopathologic data are necessary to determine the 155 
optimal imaging modality for the delineation of diffuse gliomas. Using combined PET-156 
MRI will help to reduce the number of scans necessary for multimodality imaging, while 157 
frameless stereotactic techniques will facilitate the acquisition of multiple image-guided 158 
biopsies with good accuracy within a limited time.  159 
 160 
The importance of adequate glioma delineation is underscored by reports describing 161 
that (near) radiologically complete resection of MRI abnormalities (T1-weighted 162 
gadolinium-enhanced MRI for HGG and on T2/FLAIR-weighted MRI for LGG) is 163 
correlated with improved survival. 12-17 A resection based on modalities with superior 164 
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delineation could result in even more complete resection and thus holds promise for 165 
even longer survival, and conversely to identify patients with glioma infiltration beyond 166 
meaningful surgical therapy, so that useless, and possibly harmful, resections can be 167 
avoided. Moreover, evidence accumulates that subsequent therapeutic modalities are 168 
more successful after resection that is as complete as possible. 16 169 
 170 
Trial status 171 
Patient recruitment was initiated on September 1, 2014.  172 
 173 
Safety Considerations 174 
Because neuronavigated biopsy has a risk of less than 2% of intracranial hemorrhage 175 
with consequences for the patient, the number of biopsy trajectories is limited to three. 176 
18, 19 Since the biopsy procedure is immediately followed by a craniotomy for tumor 177 
resection, possible hemorrhages can be directly identified and removed. The tumor 178 
resection will be performed according to standard care. 179 
All adverse events reported spontaneously by the subject or observed by the investiga-180 
tor or his staff will be recorded in the protocol case report forms (CRF) using the 181 
Common Terminology Criteria for Adverse Events classification. 20 All serious adverse 182 
events (SAEs) will be reported through the web portal ToetsingOnline 183 
(https://www.toetsingonline.nl) to the accredited Medical Ethical Committee (METC) 184 
that approved the protocol. SAEs that result in death or are life threatening are reported 185 
expeditiously. 186 
 187 
Follow-up 188 
All patients will receive standard follow-up, which consists of postoperative clinical 189 
admission for as long as needed and an outpatient appointment eight weeks after the 190 
procedure. Apart from that, postoperative adjuvant chemo- and/or radiotherapy will be 191 
installed according to histopathologic and molecular classification of the tumor, as 192 
discussed postoperatively at the neuro-oncology tumor board meetings. All adverse 193 
events will be followed until they have abated, or until a stable situation has been 194 
reached.  195 
 196 
Data Management and Statistical Analysis 197 
Data will be collected on electronic CRF (eCRF). The eCRF is only assessable by the 198 
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principal and the study investigator. The eCRF will be completed on site by an 199 
investigator. The principal investigator will review the collected data. 200 
The number of biopsies and patients required to compare the area under the curve 201 
(AUC) of the receiver operating characteristic (ROC) curves depend on the reference 202 
AUC (t1), the minimal relevant AUC from the improved imaging (t2), the ratio of non-203 
tumor and tumor biopsies (ratio), the correlation of imaging within patients (r), the 204 
average number of biopsies per patient (s), the correlation of histopathologic 205 
quantification between biopsies within patients (rho), the type I error (alpha) and the 206 
type II error (beta) 21-23. Under the assumptions of t1 0.6, t2 0.8, ratio 0.25, r 0.5, s 6, rho 207 
0.2, alpha 0.05 and beta 0.2, 20 patients per glioma target volume subgroup are 208 
required. The overall study population then comprises 20 non-enhancing and 20 209 
enhancing glioma patients, each stratum providing at least 120 biopsies. For testing the 210 
correlation between simplified and full quantitative measurement of input function in 211 
dynamic PET scanning a sample size of eight is mostly used in pilot studies. Due to the 212 
experience with other trials we will include this number in phase I. In phase II 32 213 
patients will be included to obtain the total of 40 patients from our sample size 214 
calculation. 215 
Continuous variables will be described as a mean with standard deviation if the 216 
distribution is symmetric and as a median with minimum and maximum if it is skewed. 217 
Categorical variables are presented as numbers with percentages. Data analysis will be 218 
performed using R. AUCs are compared using a nonparametric resampling test using 219 
pROC in R. 24-26 Next, multivariate logistic regression analysis modeling histopathology 220 
by quantitative imaging is performed using Bayesian models.  221 
 222 
Quality Assurance 223 
As the METC of VU University Medical Center (VUmc) decided it was unnecessary to 224 
appoint a Data Safety Monitoring Board for this study, the progress of this study will be 225 
monitored by the Clinical Research Bureau of VUmc. 226 
 227 
Expected Outcomes of the Study 228 
We expect that advanced imaging in combination with standard imaging, will have a 229 
superior diagnostic accuracy for glioma delineation compared with current standard 230 
imaging. This delineation could help neurosurgeons, neurologists, radiation oncologists 231 
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and medical oncologists in their clinical decision-making.  Next, studies comparing 232 
glioma resection or radiotherapy using standard versus standard plus advanced imaging 233 
can be conducted to investigate possible influences on clinical outcome.  234 
The expected correlation between advanced imaging and histologic and molecular 235 
characteristics could provide biomarkers for prognosis and choice of therapy, as well as 236 
further insight into glioma imaging  237 
 238 
Duration of the Project 239 
We anticipate that phase I will take 12 months and phase II 24 months, aiming for a total 240 
study duration of three years.  241 
 242 
Project Management 243 
The principal investigator, Dr. de Witt Hamer, will lead the study. Dr. Pouwels will be 244 
responsible for the MRS data, Dr. Barkhof for the MRI data, Dr Boellaard and Dr. 245 
Hoekstra for the PET data, and Dr. Wesseling for the pathology data. The study 246 
investigator, Mr. Verburg, MSc, will coordinate the logistics and of the study as well as 247 
the interpretation of the results.  248 
 249 
Ethics 250 
The study is approved by the METC of VUmc and will be conducted according to the 251 
principles of the Declaration of Helsinki and in accordance with the Medical Research 252 
Involving Human Subjects Act. Explicit written consent will be obtained from all patients 253 
in this study. 254 
Disclosures 255 
Financial support was provided by grant CCA2012-2-05 of the Cancer Center 256 
Amsterdam (CCA) of the VU University Medical Center and grant OAA/H1/VU 2015-257 
7502 of the Dutch Cancer Society. 258 
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 334 
Figures and Tables 335 
Table. 1 Inclusion/Exclusion/Withdrawal criteria. MRI = magnetic resonance imaging, 336 
PET = positron emission tomography 337 
 338 
Fig. 1 Imaging protocol for different phases study. Cho = 11C-Choline, FET = 339 
[18F]Fluoroethyl-tyrosine 340 
 341 
Table.2 Quantitative imaging parameters. MRI = magnetic resonance imaging, PET = 342 
positron emission tomography, FLAIR = Fluid attenuated inversion recovery, T/N ratio = 343 
tumor-to-normal radioactivity (PET) or signal intensity (MRI), MRS = Magnetic 344 
Resonance Spectroscopy, Cho = choline, NAA = N-acetyl aspartate, ASL = Arterial Spin 345 
Labeling, CBF = Cerebral Blood Flow, DTI = Diffusion Tensor Imaging, FA = Fractional 346 
Anisotropy, ADC = Apparent Diffusion Coefficient, DSC = Dynamic Susceptibility 347 
Contrast, CBV = Cerebral Blood Volume, SUV = Standardized uptake value 348 
 349 
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